New research on mice raises hope of a better, more lasting treatment for macular degeneration, which uses a class of drugs known as MDM2 inhibitors to regress the abnormal blood vessels responsible for the vision loss associated with the disease. Researchers at the University of North Carolina (UNC) School of Medicine and colleagues write about their findings in a recent online issue of the Journal of Clinical Investigation. The best treatment that is currently available uses an antibody, anti-VEGF, that is injected into the eye. But the injection has to be given every 4 or 8 weeks, depending on the brand, which makes it expensive and time-consuming, plus it exposes the patient to risk of infection. In June 2011, a US Food and Drug Administration (FDA) panel approved an anti-VEGF treatment of wet AMD that only has to be injected every 8 weeks. To see more details visit, www.medicalnewstoday.com